Skip to main content

Mesnex Disease Interactions

There are 2 disease interactions with Mesnex (mesna).

Major

MDVs (applies to Mesnex) prematurity

Major Potential Hazard, Moderate plausibility. Applicable conditions: Prematurity/Underweight in Infancy

Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative. Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight. When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants. Thus, single-dose formulations should always be used in infants whenever possible. However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated. The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns. However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered. The level at which toxicity may occur is unknown.

References

  1. (2001) "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn
  2. (2001) "Product Information. Mesnex (mesna)." Bristol-Myers Squibb
  3. (2001) "Product Information. Mivacron (mivacurium)." Glaxo Wellcome
  4. (2001) "Product Information. Nuromax (doxacurium)." Glaxo Wellcome
  5. (2001) "Product Information. Tracrium (atracurium)." Glaxo Wellcome
  6. (1997) "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html. Pediatrics, 99, p. 268-78
View all 6 references
Major

Mesna (applies to Mesnex) autoimmune disorders

Major Potential Hazard, Moderate plausibility.

Mesna is a thiol (SH) compound. Hypersensitivity reactions including anaphylaxis have occurred in patients with autoimmune disorders, the majority of whom received high dosages of mesna orally. Therapy with mesna should be administered cautiously in patients with autoimmune disorders.

References

  1. Zonzits E, Aberer W, Tappeiner G (1992) "Drug eruptions from mesna. After cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis." Arch Dermatol, 128, p. 80-2
  2. Lang E, Goos M (1985) "Hypersensitivity to mesna." Lancet, 2, p. 329
  3. Reinhold-Keller E, Mohr J, Christophers E, Nordmann K, Gross WL (1992) "Mesna side effects which imitate vasculitis." Clin Investig, 70, p. 698-704
  4. Seidel A, Andrassy K, Ritz E, Kasser U, Lemmel EM (1991) "Allergic reactions to mesna." Lancet, 338, p. 381
  5. (2001) "Product Information. Mesnex (mesna)." Bristol-Myers Squibb
View all 5 references

Mesnex drug interactions

There are 3 drug interactions with Mesnex (mesna).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.